Avidity Biosciences Inc Aktie News

The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

MILWAUKEE , Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity shareholders. Halper Sadeh encourages Avidity shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avidity Biosciences, Inc. (NasdaqGM: RNA) to Novartis AG. Under the terms of the proposed transaction, shareholders of Avidity will receive $72.00 in cash for each share of Avidity that they own. KSF is...

It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space.

Shares of Avidity Biosciences (RNA) soared more than 40% Monday after Novartis (NVS) agreed to buy the U.S. biopharmaceutical firm for about $12 billion in cash to expand its RNA-based disease-fighting pipeline.

Novartis (NYSE: NVS) revealed plans of acquiring Avidity Biosciences Inc (NASDAQ: RNA) in a $12 billion all-cash transaction – valuing each share of the biotech company at $72 on Monday. The announcement sent RNA shares soaring roughly 44% in a single session – indicating investor enthusiasm and confidence in the buyout terms.